The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial
Open accessAbstract
CONTEXT: Sentinel lymph node dissection (SLND) accurately identifies nodal metastasis of early breast cancer, but it is not clear whether further nodal dissection affects survival. OBJECTIVE: To determine the effects of complete axillary lymph node dissection (ALND) on survival of patients with sentinel lymph node (SLN) metastasis of breast cancer. DESIGN, SETTING, AND PATIENTS: The American College of Surgeons Oncology Group Z0011 trial, a phase 3 noninferiority trial conducted at 115 sites and enrolling patients from May 1999 to December 2004. Patients were women with clinical T1-T2 invasive breast cancer, no palpable adenopathy, and 1 to 2 SLNs containing metastases identified by frozen section, touch preparation, or hematoxylin-eosin staining on permanent section. Targeted enrollment was 1900 women with final analysis after 500 deaths, but the trial closed early because mortality rate was lower than expected. INTERVENTIONS: All patients underwent lumpectomy and tangential whole-breast irradiation. Those with SLN metastases identified by SLND were randomized to undergo ALND or no further axillary treatment. Those randomized to ALND underwent dissection of 10 or more nodes. Systemic therapy was at the discretion of the treating physician. MAIN OUTCOME MEASURES: Overall survival was the primary end point, with a noninferiority margin of a 1-sided hazard ratio of less than 1.3 indicating that SLND alone is noninferior to ALND. Disease-free survival was a secondary end point. RESULTS: Clinical and tumor characteristics were similar between 445 patients randomized to ALND and 446 randomized to SLND alone. However, the median number of nodes removed was 17 with ALND and 2 with SLND alone. At a median follow-up of 6.3 years (last follow-up, March 4, 2010), 5-year overall survival was 91.8% (95% confidence interval [CI], 89.1%-94.5%) with ALND and 92.5% (95% CI, 90.0%-95.1%) with SLND alone; 5-year disease-free survival was 82.2% (95% CI, 78.3%-86.3%) with ALND and 83.9% (95% CI, 80.2%-87.9%) with SLND alone. The hazard ratio for treatment-related overall survival was 0.79 (90% CI, 0.56-1.11) without adjustment and 0.87 (90% CI, 0.62-1.23) after adjusting for age and adjuvant therapy. CONCLUSION: Among patients with limited SLN metastatic breast cancer treated with breast conservation and systemic therapy, the use of SLND alone compared with ALND did not result in inferior survival. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00003855.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J.-H., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa022152 · Cited by 6,249
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686
Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., Aguilar, M., & Marubini, E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020989 · Cited by 4,450
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer
Veronesi, U., Paganelli, G., Viale, G., Luini, A., Zurrida, S., Galimberti, V., Intra, M., Veronesi, P., Robertson, C., Maisonneuve, P., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa012782 · Cited by 2,210
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Krag, D. N., Anderson, S. J., Julian, T. B., Brown, A. M., Harlow, S. P., Costantino, J. P., Ashikaga, T., Weaver, D. L., Mamounas, E. P., Jalovec, L. M., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70207-2 · Cited by 1,920
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Breast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Nomograms in oncology: more than meets the eye
Balachandran, V. P., Gonen, M., Smith, J. J., & DeMatteo, R. P. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71116-7 · Cited by 3,292
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
EBCTCG (Early Breast Cancer Trialists' Collaborative Group) (2014) · The Lancet · doi:10.1016/s0140-6736(14)60488-8 · Cited by 2,254
Giuliano, A. E., Ballman, K. V., McCall, L., Beitsch, P. D., Brennan, M. B., Kelemen, P. R., Ollila, D. W., Hansen, N. M., Whitworth, P. W., Blumencranz, P. W., et al. (2017) · JAMA · doi:10.1001/jama.2017.11470 · Cited by 1,912
Self-citationDonker, M., van Tienhoven, G., Straver, M. E., Meijnen, P., van de Velde, C. J. H., Mansel, R. E., Cataliotti, L., Westenberg, A. H., Klinkenbijl, J. H. G., Orzalesi, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70460-7 · Cited by 1,871
Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, F., Baselga, J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv221 · Cited by 1,827
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
Regional Nodal Irradiation in Early-Stage Breast Cancer
Whelan, T. J., Olivotto, I. A., Parulekar, W. R., Ackerman, I., Chua, B. H., Nabid, A., Vallis, K. A., White, J. R., Rousseau, P., Fortin, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415340 · Cited by 1,294
Galimberti, V., Cole, B. F., Zurrida, S., Viale, G., Luini, A., Veronesi, P., Baratella, P., Chifu, C., Sargenti, M., Intra, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70035-4 · Cited by 1,233
Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H.-J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx308 · Cited by 1,205
Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153
Lyman, G. H., Temin, S., Edge, S. B., Newman, L. A., Turner, R. R., Weaver, D. L., Benson, A. B., Bosserman, L. D., Burstein, H. J., Cody, H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1177 · Cited by 1,026
Self-citationBreast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein, H. J., Chew, H., Dang, C., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0030 · Cited by 951
Veronesi, U., Orecchia, R., Maisonneuve, P., Viale, G., Rotmensz, N., Sangalli, C., Luini, A., Veronesi, P., Galimberti, V., Zurrida, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70497-2 · Cited by 767
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Leiter, U., Stadler, R., Mauch, C., Hohenberger, W., Brockmeyer, N., Berking, C., Sunderkötter, C., Kaatz, M., Schulte, K.-W., Lehmann, P., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00141-8 · Cited by 707
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju066 · Cited by 615
“Furthermore, because axillary operation will increasingly be confined to sentinel node biopsy, CTCs could be a helpful tool for selection of highrisk patients who might benefit from a more aggressive dose-dense chemotherapy regimen (27,28).”
BackgroundClinical Diagnosis and Management of Breast Cancer
McDonald, E. S., Clark, A. S., Tchou, J., Zhang, P., & Freedman, G. M. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.157834 · Cited by 613
Deep learning radiomics can predict axillary lymph node status in early-stage breast cancer
Zheng, X., Yao, Z., Huang, Y., Yu, Y., Wang, Y., Liu, Y., Mao, R., Li, F., Xiao, Y., Wang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15027-z · Cited by 607
Bandi, P., Geessink, O., Manson, Q., Van Dijk, M., Balkenhol, M., Hermsen, M., Ehteshami Bejnordi, B., Lee, B., Paeng, K., Zhong, A., et al. (2019) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2018.2867350 · Cited by 569
Gentilini, O. D., Botteri, E., Sangalli, C., Galimberti, V., Porpiglia, M., Agresti, R., Luini, A., Viale, G., Cassano, E., Peradze, N., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.3759 · Cited by 568
Biganzoli, L., Wildiers, H., Oakman, C., Marotti, L., Loibl, S., Kunkler, I., Reed, M., Ciatto, S., Voogd, A. C., Brain, E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70383-7 · Cited by 567
Overview of Breast Cancer Therapy
Moo, T.-A., Sanford, R., Dang, C., & Morrow, M. (2018) · PET Clinics · doi:10.1016/j.cpet.2018.02.006 · Cited by 551
Circulating tumour cells in non-metastatic breast cancer: a prospective study
Lucci, A., Hall, C. S., Lodhi, A. K., Bhattacharyya, A., Anderson, A. E., Xiao, L., Bedrosian, I., Kuerer, H. M., & Krishnamurthy, S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70209-7 · Cited by 507
Giuliano, A. E., Ballman, K., McCall, L., Beitsch, P., Whitworth, P. W., Blumencranz, P., Leitch, A. M., Saha, S., Morrow, M., & Hunt, K. K. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001863 · Cited by 497
Self-citationSteiner, D. F., MacDonald, R., Liu, Y., Truszkowski, P., Hipp, J. D., Gammage, C., Thng, F., Peng, L., & Stumpe, M. C. (2018) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001151 · Cited by 489
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Penault-Llorca, F., Poortmans, P., Thompson, A., Zackrisson, S., & Cardoso, F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt284 · Cited by 479
Pereira, E. R., Kedrin, D., Seano, G., Gautier, O., Meijer, E. F. J., Jones, D., Chin, S.-M., Kitahara, S., Bouta, E. M., Chang, J., et al. (2018) · Science · doi:10.1126/science.aal3622 · Cited by 477
MRI for breast cancer screening, diagnosis, and treatment
Morrow, M., Waters, J., & Morris, E. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61350-0 · Cited by 448
Donker, M., Straver, M. E., Wesseling, J., Loo, C. E., Schot, M., Drukker, C. A., van Tinteren, H., Sonke, G. S., Rutgers, E. J. T., & Vrancken Peeters, M.-J. T. F. D. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000558 · Cited by 429
Eccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., Blaydes, J. P., Brennan, K., Brown, N. J., Bryant, H. E., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3493 · Cited by 421
1399 H&E-stained sentinel lymph node sections of breast cancer patients: the CAMELYON dataset
Litjens, G., Bandi, P., Ehteshami Bejnordi, B., Geessink, O., Balkenhol, M., Bult, P., Halilovic, A., Hermsen, M., van de Loo, R., Vogels, R., et al. (2018) · GigaScience · doi:10.1093/gigascience/giy065 · Cited by 418
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Axillary Nodal Evaluation in Breast Cancer: State of the Art
Chang, J. M., Leung, J. W. T., Moy, L., Ha, S. M., & Moon, W. K. (2020) · Radiology · doi:10.1148/radiol.2020192534 · Cited by 387
Metastasis-Initiating Cells and Ecosystems
Massagué, J., & Ganesh, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0010 · Cited by 372
Contemporary radiotherapy: present and future
Chandra, R. A., Keane, F. K., Voncken, F. E. M., & Thomas, C. R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00233-6 · Cited by 380
Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments
Gillespie, T. C., Sayegh, H. E., Brunelle, C. L., Daniell, K. M., & Taghian, A. G. (2018) · Gland Surgery · doi:10.21037/gs.2017.11.04 · Cited by 361
Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., Hudis, C. A., Hwang, E. S., Kirshner, J. J., Morrow, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1188 · Cited by 340
Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies
Mahvi, D. A., Liu, R., Grinstaff, M. W., Colson, Y. L., & Raut, C. P. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21498 · Cited by 338
Lymphedema following breast cancer treatment and impact on quality of life: A review
Taghian, N. R., Miller, C. L., Jammallo, L. S., O’Toole, J., & Skolny, M. N. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.06.004 · Cited by 333
Pathogenesis, prevention, diagnosis and treatment of breast cancer
Shah, R. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.283 · Cited by 329
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
Reimer, T., Stachs, A., Veselinovic, K., Kühn, T., Heil, J., Polata, S., Marmé, F., Müller, T., Hildebrandt, G., Krug, D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2412063 · Cited by 313
Clinical implications of cancer self-seeding
Comen, E., Norton, L., & Massagué, J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.64 · Cited by 312
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
de Boniface, J., Filtenborg Tvedskov, T., Rydén, L., Szulkin, R., Reimer, T., Kühn, T., Kontos, M., Gentilini, O. D., Olofsson Bagge, R., Sund, M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313487 · Cited by 307
Cardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., Gentilini, O., Peccatori, F., Fourquet, A., Delaloge, S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.004 · Cited by 304
Ng, B., Chu, A., & Khan, M. M. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002468 · Cited by 301
Gold Nanoparticles: Recent Advances in the Biomedical Applications
Zhang, X. (2015) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-015-0529-4 · Cited by 299
Giammarile, F., Alazraki, N., Aarsvold, J. N., Audisio, R. A., Glass, E., Grant, S. F., Kunikowska, J., Leidenius, M., Moncayo, V. M., Uren, R. F., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2544-2 · Cited by 284
Progress in adjuvant systemic therapy for breast cancer
Pondé, N. F., Zardavas, D., & Piccart, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0089-9 · Cited by 281
Past, Present, and Future Challenges in Breast Cancer Treatment
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., & Wolff, A. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4139 · Cited by 277
Warren, L. E. G., Miller, C. L., Horick, N., Skolny, M. N., Jammallo, L. S., Sadek, B. T., Shenouda, M. N., O'Toole, J. A., MacDonald, S. M., Specht, M. C., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.11.232 · Cited by 274
Gold nanoparticles in breast cancer treatment: Promise and potential pitfalls
Lee, J., Chatterjee, D. K., Lee, M. H., & Krishnan, S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.006 · Cited by 271
Brackstone, M., Baldassarre, F. G., Perera, F. E., Cil, T., Chavez Mac Gregor, M., Dayes, I. S., Engel, J., Horton, J. K., King, T. A., Kornecki, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00934 · Cited by 271
Sun, Q., Lin, X., Zhao, Y., Li, L., Yan, K., Liang, D., Sun, D., & Li, Z.-C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00053 · Cited by 263
Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review
Pilewskie, M., & Morrow, M. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4163 · Cited by 262
Mejdahl, M. K., Andersen, K. G., Gartner, R., Kroman, N., & Kehlet, H. (2013) · BMJ · doi:10.1136/bmj.f1865 · Cited by 258
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Cardoso, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr371 · Cited by 256
Diego, E. J., McAuliffe, P. F., Soran, A., McGuire, K. P., Johnson, R. R., Bonaventura, M., & Ahrendt, G. M. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5052-8 · Cited by 159
Schou Bredal, I., Smeby, N. A., Ottesen, S., Warncke, T., & Schlichting, E. (2014) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.12.239 · Cited by 123
Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications
Bhat, V., Pellizzari, S., Allan, A. L., Wong, E., Lock, M., Brackstone, M., Lohmann, A. E., Cescon, D. W., & Parsyan, A. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103566 · Cited by 31
Metadata
- Authors
- Giuliano, A. E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-02-09
- Volume
- 305
- Issue
- 6
- Pages
- 569
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2096785769
- Cited by
- 2,942
- References
- 35
- FWCI
- 89.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.